Pacira BioSciences

PCRX

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$24.67

+0.84 (+3.52%)

Market Cap

$970.4M

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Exceptional

Stability

Mixed

Valuation

Good

Track this stock — start free trial

Share count falling — buybacks

−1.3% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 45.6M (2021) → 45.0M (2025)

Winston Score History

The full picture

Pacira BioSciences is a pharmaceutical company that makes drugs to help patients manage pain after surgery. Its main product is EXPAREL, a long-acting local anesthetic injected directly at the surgical site to reduce the need for opioid painkillers. The company sells primarily to hospitals and surgical centers across the United States, and it also offers ZILRETTA, a knee injection for osteoarthritis pain.

Pacira earns revenue by selling these specialty drugs directly to healthcare providers, with EXPAREL making up the large majority of its sales. The company operates almost entirely in the U.S. market and generates roughly $600–700 million in annual revenue. Its competitive edge comes from EXPAREL's unique extended-release technology, which makes it harder for rivals to copy, but the drug faces competition from cheaper generic pain management options and nerve-block techniques. The key risk going forward is whether Pacira can grow EXPAREL adoption broadly enough to offset pricing pressure and fund its pipeline of new products.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+209.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$117M/ year

↑ Rising (+44% vs prior year)

16.1% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

4.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$275M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Pacira BioSciences is putting 16% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-73.3%

Thin — -73.3% gross margin

Profit after running costs

Operating Margin

2.2%

Thin — 2.2% operating margin

Return on the money invested

ROCE

1.8%

Weak — 1.8% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+5.7%

Slow sales growth (+5.7% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

1282%

Turns 1282% of profit into real cash

Spare cash per sale

FCF Margin

24.1%

Converts sales into free cash efficiently (24.1%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.54

Conservative — low debt load (0.54)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

70.1x

Expensive — P/E 70.1

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+64.8

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (70.1 → 5.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial